vator of Rho family GTP binding proteins, pEFC3) was com-HMG CoA reductase is a rate-limiting enzyme in a pletely suppressed when compared with RMC cotransfected with empty vector, pEF. Because geranylgeranylation is usually cholesterol biosynthetic mevalonate pathway (Fig. 1) . 
induced diabetic rats that lovastatin significantly supstatin suppresses both control and high glucose (HG)-induced pressed glomerular transforming growth factor (TGF)-␤1 TGF-␤1 and fibronectin mRNA expression and protein syntheexpression in 4 days and urinary albumin excretion in 4 sis by rat mesangial cell (RMC) and that this down-regulation weeks; it also reduced glomerular volume in 2 weeks by lovastatin is reversed by mevalonate. It was postulated that after induction of diabetes mellitus [2] . In this study, this down-regulation may be linked to signaling of small guanine triphosphate (GTP)-binding proteins and mediated by the lovastatin suppressed serum cholesterol level in diabetic limitation of isoprenoids such as farnesylpyrophosphate (FPP) rats only after 6 months, suggesting that lovastatin may and geranylgeranylpyrophosphate (GGPP) in RMC. To deterhave renal protective effect independent of lipid lowmine the isoprenoid and small GTP-binding proteins involved ering action. Park et al [3] found that lovastatin reduced in TGF-␤1 and fibronectin expression, FPP or GGPP was mesangial proliferation and glomerular macrophage inadded alone or in combination to RMC treated with lovastatin cultured under normal or high glucose condition. Suppression filtration before any increase in extracellular matrix in of TGF-␤1 and fibronectin expression by lovastatin was renephrotic rats. These observations suggest that lovastatversed effectively when GGPP was added alone. Partial reverin's effect on albuminuria and glomerular hypertrophy sal of lovastatin effect on fibronectin and TGF-␤1 expression may be related to modulation of early cellular events in was found when FPP was added alone. Adding both GGPP and FPP resulted in complete reversal of lovastatin effect on a diabetic kidney.
fibronectin but not TGF-␤1 suggesting that fibronectin and TGF-␤1 are regulated differently. Furthermore, luciferase activity of RMC cotransfected with fibronectin promoter reporter CELLULAR EFFECTS OF HMG CoA system and plasmid-expressing C3 exoenzyme (a specific inacti-
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vator of Rho family GTP binding proteins, pEFC3) was com-HMG CoA reductase is a rate-limiting enzyme in a pletely suppressed when compared with RMC cotransfected with empty vector, pEF. Because geranylgeranylation is usually cholesterol biosynthetic mevalonate pathway (Fig. 1) . 
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Ras and/or Raf resulting in triggering of Raf-MEK1-ERK cascade [13, 14] . Some evidence suggests that Rho family small GTP binding proteins are involved in PKC activation [15] and translocation to plasma membrane [16] . However, the precise signaling network between Rho family GTP binding proteins and an individual isoform of PKC still remains to be elucidated.
LOVASTATIN DOWN-REGULATES EXPRESSION OF TGF-␤1 IN RAT GLOMERULI AND MESANGIAL CELLS
We demonstrated that the glomerular TGF-␤1 expression in STZ-induced diabetic rats was suppressed by lovastatin at day 2 after treatment [4] and this effect by lovastatin was sustained for up to 3 months [2] . Increased TGF-␤1 expression by HG (30 mmol/L) in rat mesangial on the TGF-␤1 promoter region; they are the major responsible for activation of a mitogen-activated protein elements responsible for the tetradecanoylphorbol acekinase (MAPK) pathway cascade (Raf-MEK1-extraceltate (TPA) activation and TGF-␤1 autoinduction [17] .
lular regulated kinase [ERK]). Intracellular signaling
Other transcription factor binding sites including Sp1, pathways induced by Rho family proteins activate stress-CRE, NF-B, and Egr-1 are also found in the TGF-␤1 activated protein kinase/c-Jun N-terminal protein kinase promoter region. Other evidence suggests that Sp1 is re-(SAPK/JNK) and p38 MAPK. These kinases also actisponsible for the expression of TGF-␤1 and TGF-␤3 [18] . vate various transcription factors including Elk1, cyclic A putative glucose responsible element (GLURE), CAC adenosine monophosphate (cAMP) Ϫ responsible ele-GTG was also found in the promoter region (Ϫ1040 ϳ ment binding protein (CREB), nuclear transcription fac-Ϫ1009) of human TGF-␤1 gene as was shown in mouse tor (ATF)-2, AP-1, NF-B, and Myc (Fig. 2) . Therefore, TGF-␤1 gene [19] . the decrease in membrane bound small GTP binding SAPK/JNK or p38 MAPK signaling pathways are preproteins reduces expression and activation of various sumably activated by Rho family small GTP-binding protranscription factors leading to down-regulation of variteins rather than Raf-MEK-ERK pathway activated by ous gene expression. Although the expression of various Ras protein may regulate TGF-␤1 expression because genes are regulated by inhibitor of HMG CoA reductase the SAPK/JNK and p38 MAPK cascades also activate through small GTP binding proteins, the precise signal-AP-1. In addition, ERK MAPK can be activated by Rho A ing pathways responsible for the expression of genes enthrough unspecified signaling pathway. Therefore, it is coding TGF-␤ and extracellular matrix (ECM) proteins suggested that lovastatin suppresses expression of TGF-␤1 induced by high glucose (HG) are not defined clearly.
induced by control or HG through decreased activation Another important intracellular signaling molecule acof the transcription factors as a result of the reduction tivated by HG is protein kinase C (PKC) [12] . It has of functional Rho family small GTP-binding proteins on plasma membrane. been established that certain isoforms of PKC stimulate lovastatin induced an increase in activity and amount of tPA and uPA, and a decrease in plasminogen activator inhibitor-1 (PAI-1). A similar result was obtained from EFFECTS OF LOVASTATIN ON the cultured primary renal proximal tubular cells. In the ECM METABOLISM cell culture study, however, no uPA activity was detected. Changes in plasminogen activator/plasmin system by loRecent studies suggested that lovastatin and other inhibitors of HMG CoA reductase reduce ECM accumulavastatin were reversed by mevalonate and GGPP and by treatment with C3 exoenzyme, an inactivator of Rho tion through two possible ways; the suppression of ECM synthesis and the enhancement of ECM degradation.
family GTP-binding proteins.
We have also demonstrated that lovastatin suppressed Nishimura et al [8] reported that pravastatin inhibited fetal calf serum-stimulated type IV collagen secretion fibronectin mRNA and protein synthesis induced by HG in RMC. This lovastatin effect was reversed by the addiand mRNA expression by mesangial cells and that GGPP and mevalonate reversed the effects of pravation of GGPP (Fig. 4) as well as mevalonate [2] . Addition of FPP allowed only partial reversion of suppressive efstatin nearly completely. The pravastatin effects on type IV collagen secretion and expression may depend on fect of lovastatin on fibronectin expression. By adding
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lovastatin exerts its renal protective effects in experimentally induced diabetes through inactivation of Rho family small GTP-binding proteins.
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